GlassScriptPhysician profile
Dileep Puppala
NPI 1215989900
$107,536.06
in general payments reported to CMS, 2019-2025
63 companies · $5,738 in 2025
The $5,738 reported for 2025 was more than what 89% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $31K · 2021: $17K · 2022: $10K · 2023: $5,053 · 2024: $3,089 · 2025: $5,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $650 · Travel and Lodging: $408 · Education: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,598.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $650.00 |
| Travel and Lodging | $408.01 |
| Education | $223.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $43,853.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $16,590.88 | 2019-2025 | |
| Mylan Specialty L.P. | $14,843.24 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $8,756.65 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $7,240.72 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Inspire Medical Systems, INC. | $3,904.86 | 2022-2025 | Inspire |
| Actelion Pharmaceuticals US, INC. | $2,054.67 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Jazz Pharmaceuticals INC. | $1,604.57 | 2019-2025 | |
| Insmed, INC. | $957.47 | 2020-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $723.21 | 2019-2025 | Xolair |
| Amgen INC. | $624.30 | 2021-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.58 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $462.56 | 2020-2025 | Acthar |
| Harmony Biosciences LLC | $415.66 | 2020-2025 | Wakix |
| Philips North America LLC | $391.75 | 2019-2025 | (Ak6) Vest Therapy, (2383) Sleepundivided, Vest Therapy Und |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $347.68 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $324.35 | 2019-2025 | Prolastin-C Liquid, Xembify |
| United Therapeutics Corporation | $305.93 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $252.78 | 2019-2025 | Winrevair, Keytruda |
| Optinose US, INC. | $245.69 | 2019-2024 | |
| Allergan, INC. | $232.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $225.44 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $224.67 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $170.28 | 2023-2025 | Aralast, Takhzyro |
| Baxter Healthcare | $167.53 | 2020-2024 | Hillrom - Vest System Model 105 Home Care |
| Pulmonx Corporation | $161.06 | 2023 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Verona Pharma, INC. | $158.77 | 2025 | Ohtuvayre |
| Inogen, INC. | $144.91 | 2022-2024 | Inogen One G3 Oxygen Concentrator, Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pfizer INC. | $124.73 | 2020-2025 | |
| Abbvie INC. | $119.97 | 2021-2022 | |
| Octapharma USA, INC. | $117.14 | 2021-2023 | Cutaquig |
| Ethicon US, LLC | $113.00 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $100.71 | 2024-2025 | Lumryz |
| Viatris Specialty LLC | $100.37 | 2025 | Yupelri |
| Intuitive Surgical, INC. | $91.71 | 2025 | |
| Shionogi INC | $85.58 | 2023-2024 | Fetroja |
| Electromed, INC. | $59.55 | 2022 | |
| Ani Pharmaceuticals, INC. | $57.71 | 2023-2024 | Purified Cortrophin Gel |
| Zoll Respicardia, INC. | $54.19 | 2024-2025 | Remede System |
| E.R. Squibb & Sons, L.L.C. | $52.66 | 2019-2021 | |
| Resmed Corp | $48.82 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $46.71 | 2020 | |
| Tactile Systems Technology INC | $35.44 | 2024 | Flexitouch Plus, Entre Plus |
| Chiesi USA, INC. | $33.29 | 2021 | |
| Paratek Pharmaceuticals, INC. | $32.88 | 2022-2024 | Nuzyra |
| Vifor Pharma, INC. | $30.96 | 2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $30.33 | 2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $28.72 | 2019 | |
| Alcresta Therapeutics, INC. | $28.00 | 2024 | Relizorb |
| Teva Pharmaceuticals USA, INC. | $27.05 | 2019-2020 | |
| Advanced Respiratory, INC | $21.04 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $20.85 | 2025 | Neffy |
| Pharming Healthcare, INC. | $17.89 | 2023 | Ruconest |
| Melinta Therapeutics, LLC | $17.11 | 2022 | |
| Lilly USA, LLC | $15.45 | 2025 | Zepbound, Mounjaro |
| Circassia INC. | $15.38 | 2019 | |
| Abbott Laboratories | $14.93 | 2024 | Cardiomems |
| Gilead Sciences, INC. | $13.76 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dileep Puppala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.